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Abstract
Pathogenic isolates of Klebsiella pneumoniae (K. pneumoniae), particularly the extended-spectrum β-lactamase
(ESBL) producing strains, are mostly associated with the failure of antibiotic therapy in nosocomial infections. The
present work was designed to evaluate the impact of Mr. Trivedi’s biofield energy treatment on phenotypic and
genotypic characteristics of K. pneumoniae. The strain of K. pneumoniae bearing ATCC 15380 (American Type
Culture Collection) was procured from the Bangalore Genei, in sealed pack and divided into control and treated
groups. Treated group was subjected to Mr. Trivedi’s biofield energy treatment and analyzed for the antimicrobial
susceptibility, minimum inhibitory concentration (MIC), biochemical reactions, and biotyping using automated
MicroScan Walk-Away® system. Further, the effect of biofield treatment was also evaluated using Random Amplified
Polymorphic DNA (RAPD) in order to determine their epidemiological relatedness and genetic characteristics of
biofield treated K. pneumoniae samples. The antimicrobial susceptibility results showed an improve sensitivity (i.e.
from intermediate to susceptible) of ampicillin/sulbactam and chloramphenicol, while altered sensitivity of
cephalothin (i.e. from susceptible to intermediate) was also reported as compared to the control sample. The MIC
value showed two-fold decrease in MIC value of ampicillin/sulbactam (i.e. 16/8 to ≤8/4 µg/mL) and chloramphenicol
(i.e. 16 to ≤ 8 µg/mL) as compared to the control. The cephalothin showed two-folds change (i.e. ≤ 8 to 16 µg/mL) in
the MIC value as compared with the control. Biofield treatment showed 9.09% alterations in biochemical reactions
followed by a change in biotype number (7774 4272) in the treated group with respect to the control (7774 4274).
Genetic fingerprinting was performed on control and treated samples using RAPD-PCR biomarkers, which showed
an average range of 11 to 15% of polymorphism among the treated samples with respect to the control. These
results suggested that Mr. Trivedi’s biofield energy treatment has a significant impact on K. pneumoniae.
Keywords: Klebsiella pneumoniae; Biofield energy treatment;
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Amplified Polymorphic DNA.
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Introduction
The increased medical practice for antibiotic usage creates selection
pressure and results emergence of nosocomial pathogens. Klebsiella
pneumoniae (K. pneumoniae) is a Gram-negative, facultative
anaerobic and rod-shaped bacterium of the Enterobacteriaceae family.
It is regarded as an opportunistic pathogen that is associated with the
hospital-acquired urinary tract infections, septicemia, pneumonia, and
soft tissue infections [1]. K. pneumoniae is responsible for the
nosocomial outbreaks worldwide, due to its ability to spread rapidly in
the hospital environment [2], and results in high morbidity and
mortality [3]. It has acquired resistance against extended-spectrum
cephalosporins and penicillins, due to the production of extended-
spectrum β-lactamases (ESBLs) [4].
Multidrug combination therapy and some alternate treatment
options are required to control the infections associated with this
microorganism. Due to the associated side effects and failure of drug
treatment therapy, alternate and complementary therapy approach are
the preferred treatment strategies. Recently, an alternate treatment
approach using healing therapy or therapeutic touch known as biofield
energy treatment, which has been widely reported in various research
field. The biofield therapies (putative energy fields) were reported to
alter the sensitivity of antimicrobial against treated microorganism [5],
inhibits the growth of bacterial cultures [6], effect on in vitro cells,
tissues [7], animals [8], and the clinical effects such as hematologic [9],
immunologic effects [10], healing rates of wounds [11], etc. Biofield is
the name given to the electromagnetic field that permeates and
surrounds living organisms [12]. It is referred as the biologically
produced electromagnetic and subtle energy field that provides
regulatory and communication functions within the human organism.
Specific environmental frequencies, are absorbed by the different
biomolecules, due to changes in the movements of component parts.
Therefore, the human or any living object, not only radiate but also
absorb and respond to these frequencies [13]. Mr. Mahendra Kumar
Trivedi is well known biofield treatment practitioners, and his unique
biofield energy treatment is known as The Trivedi Effect®. Mr. Trivedi’s
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biofield energy treatment has been well known and studied in the field
of materials science research [14 -16], agricultural science research
[17,18], and microbiology research [19,20].
Due to the clinical importance of K. pneumoniae and outstanding
results of biofield treatment, the present study was designed to evaluate
the impact of Mr. Trivedi’s biofield energy treatment on K.
pneumoniae with respect to the antimicrobial susceptibility,
biochemical study, and biotype number. Further, in order to study the
phenotypic characteristics of biofield treated K. pneumoniae,
molecular typing using arbitrary amplification of polymorphic DNA
sequences, termed as random amplified polymorphic DNA (RAPD)
analysis was used [21]. RAPD is a preferred technique used in different
studies for typing and discriminating the epidemiology of
microorganism [22]. RAPD has an advantage over other traditional
phenotypic typing methods as it is rapid, relatively inexpensive and
technically feasible [23]. The aim of this study was to evaluate the
impact of Mr. Trivedi’s biofield energy treatment on K. pneumoniae
with respect to antibiogram characteristics and genotyping using
RAPD of the organism.
Materials and Methods
K. pneumoniae ATCC 15380 [American Type Culture Collection]
was procured from Bangalore Genei, in sealed pack, and stored as per
the recommended storage conditions for further use. The antimicrobial
susceptibility, minimum inhibitory concentration (MIC), biochemical
reactions, and biotype number were evaluated using automated
MicroScan Walk-Away® system (Dade Behring Inc., West Sacramento,
CA) using Negative Breakpoint Combo 30 (NBPC 30) panel. RAPD
was carried out using Ultrapure Genomic DNA Prep Kit; Cat KT 83
(Bangalore Genei, India). All the tested antimicrobials, biochemicals,
media, and reagents were procured from Sigma-Aldrich, India.
Biofield treatment modalities
K. pneumoniae strain was divided into two groups i.e. control and
treated. The treated group was in sealed pack and handed over to Mr.
Trivedi for the biofield energy treatment under laboratory conditions.
Mr. Trivedi provided the treatment through his energy transmission
process to the treated group that includes bioenergy emission of
certain wavelength, which has the ability to do the changes in the
microbes without touching the sample. Mr. Trivedi’s unique energy
treatment is known as The Trivedi Effect®. Mr. Trivedi visited the
laboratory individually over a period of treatment and for control
experiments, nobody entered the experimental room during the
treatment period. Whilst handing over these cultures to Mr. Trivedi for
treatment purposes, optimum precautions were taken to avoid
contamination. After treatment, control and treated groups were
assessed on day 10 for the antimicrobial susceptibility, minimum
inhibitory concentration (MIC), biochemical reactions, biotype, and
genotyping using RAPD analysis. The result of treated sample was
compared with respect to the control.
Investigation of antimicrobial susceptibility assay
Investigation of antimicrobial susceptibility of K. pneumoniae was
carried out with the help of automated instrument, MicroScan Walk-
Away® using Negative Breakpoint Combo 30 (NBPC30) panel as per
the manufacturer’s instructions. The panel was allowed to equilibrate
to room temperature prior to rehydration. All opened panel were used
on the same day. The tests were carried out on MicroScan, which were
miniaturized of the broth dilution susceptibility test that had been
dehydrated. Briefly, 100 μL of the standardized suspension of K.
pneumoniae was pipetted into 25 mL of inoculum water using pluronic
and inverted 8-10 times and inoculated, rehydrated, and then
subjected to incubation for 16 hours at 35°C. Rehydration and
inoculation were performed using the RENOK® system with
inoculators-D (B1013-4). The detailed experimental procedures and
conditions were followed as per the manufacturer's instructions.
Briefly, after inoculation and rehydration with a standardized
suspension of K. pneumoniae, it was incubated at 35°C for 16 hours.
MIC and a qualitative susceptibility like susceptible (S), intermediate
(I), and resistant (R) were determined by observing the lowest
antimicrobial concentration showing growth inhibition [24].
Biochemical studies
The biochemical reactions of K. pneumoniae were determined by
MicroScan Walk-Away® where, interpretation of biochemical reactions
for microbial identification of Gram-negative organisms [24].
Biotype number
The biotype number of K. pneumoniae was determined by
MicroScan Walk-Away® processed panel data utilizing data of
biochemical reactions [24].
Random Amplified Polymorphic DNA (RAPD) analysis
Three series of inoculums (one for control and other two for
treatment named as treated A and B) were prepared from K.
pneumoniae sample. Two inoculums (treated samples A and B) were
subjected to Mr. Trivedi's biofield energy treatment. Whilst handing
over treated groups to Mr. Trivedi for biofield treatment, optimum
precautions were taken to avoid the contamination. After that, the
treated samples (A and B) were sub-cultured by taking 1% inoculum
and inoculated to fresh 5 mL medium and labeled as treatment A-1
and treatment B-1 respectively. Control and treated samples were
incubated at 37°C with 160 rpm for 18 h. Subsequently, the cultures
were spun down, and genomic DNA was isolated for control and
treated samples using the genomic DNA Prep Kit (Bangalore Genei,
India). The RAPD was performed with all samples of K. pneumoniae
using five RAPD primers, which were labelled as RBA 5A, RBA 10A,
RBA 15A, RBA 21A, and RBA 22A. The PCR mixture contained 2.5 μL
each of buffer, 4.0 mM each of dNTP, 2.5 μM each of primer, 5.0 μL
each of genomic DNA, 2U each of Taq polymerase, 1.5 μL of MgCl2
and 9.5 μL of nuclease-free water in a total of 25 μL mixture. PCR
amplification protocol was followed with initial denaturation at 94ºC
for 7 min, followed by 8 cycles of denaturation at 94ºC for 1 min,
annealing at 35ºC for 1 min, and extension at 72ºC for 2 min; and 35
cycle of denaturation at 94ºC for 1 min, annealing at 38ºC for 1 min,
and extension at 72ºC for 1.5 min; and the final extension at 72ºC for 7
min. Amplified PCR products (12 μL) from all the samples (control
and treated) were separated on 1.5% agarose gels at 75 volts, stained
with ethidium bromide and visualized under UV illumination [25].
The percentage of polymorphism was calculated using following
equation-
Percent polymorphism = A/B×100;
Where, A = number of polymorphic bands in treated sample; and B
= number of polymorphic bands in control.
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Results and Discussion
Antimicrobial susceptibility assay
The results of biofield treatment on K. pneumoniae with respect to
antimicrobials susceptibility pattern and MIC are summarized in Table
1 and 2, respectively.
S. No. Antimicrobial Control Treated
1 Amikacin S S
2 Amoxicillin/k-clavulanate S S
3 Ampicillin/sulbactam I S
4 Ampicillin R R
5 Aztreonam S S
6 Cefazolin S S
7 Cefepime S S
8 Cefotaxime S S
9 Cefotetan S S
10 Cefoxitin S S
11 Ceftazidime S S
12 Ceftriaxone S S
13 Cefuroxime S S
14 Cephalothin S I
15 Chloramphenicol I S
16 Ciprofloxacin S S
17 Gatifloxacin S S
18 Gentamicin S S
19 Imipenem S S
20 Levofloxacin S S
21 Meropenem S S
22 Moxifloxacin S S
23 Piperacillin/tazobactam S S
24 Piperacillin I I
25 Tetracycline S S
26 Ticarcillin/k-clavulanate S S
27 Tobramycin S S
28 Trimethoprim/sulfamethoxazole S S
R: Resistant; I: Intermediate; S: Susceptible
Table 1: Effect of biofield treatment on K. pneumoniae for its
antimicrobial susceptibility
S. No. Antimicrobial Control Treated
1 Amikacin ≤ 16 ≤ 16
2 Amoxicillin/k-clavulanate ≤ 8/4 ≤ 8/4
3 Ampicillin/sulbactam 16/8 ≤ 8/4
4 Ampicillin >16 > 16
5 Aztreonam ≤8 ≤ 8
6 Cefazolin ≤8 ≤ 8
7 Cefepime ≤ 8 ≤ 8
8 Cefotaxime ≤ 8 ≤ 8
9 Cefotetan ≤ 16 ≤ 16
10 Cefoxitin ≤ 8 ≤ 8
11 Ceftazidime ≤ 8 ≤ 8
12 Ceftriaxone ≤ 8 ≤ 8
13 Cefuroxime ≤ 4 ≤ 4
14 Cephalothin ≤ 8 16
15 Chloramphenicol 16 ≤ 8
16 Ciprofloxacin ≤ 1 ≤ 1
17 ESBL-a Scrn ≤4 ≤ 4
18 ESBL-b Scrn ≤ 1 ≤ 1
19 Gatifloxacin ≤ 2 ≤ 2
20 Gentamicin ≤ 4 ≤ 4
21 Imipenem ≤ 4 ≤ 4
22 Levofloxacin ≤ 2 ≤ 2
23 Meropenem ≤ 4 ≤ 4
24 Moxifloxacin ≤ 2 ≤ 2
25 Nitrofurantoin ≤ 32 ≤ 32
26 Norfloxacin ≤ 4 ≤ 4
27 Piperacillin/tazobactam ≤ 16 ≤ 16
28 Piperacillin 64 64
29 Tetracycline ≤ 4 ≤ 4
30 Ticarcillin/k-clavulanate ≤ 16 ≤ 16
31 Tobramycin ≤ 4 ≤ 4
32 Trimethoprim/sulfamethoxazole ≤ 2/38 ≤ 2/38
MIC values are presented in µg/mL; ESBL: Suspected extended-spectrum β-
lactamases a, b screen
Table 2: Minimum inhibitory concentration (MIC) of tested
antimicrobials against K. pneumoniae
The antimicrobial sensitivity result of three antimicrobials namely
ampicillin/sulbactam, cephalothin, and chloramphenicol showed the
alteration after biofield treatment with respect to control among
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twenty-eight tested antimicrobials. The sensitivity of ampicillin/
sulbactam and chloramphenicol was improved i.e. from intermediate
(I) to susceptible (S), while cephalothin showed an altered sensitivity
nature from S to I. Other tested antimicrobials did not show any
alterations of sensitivity pattern as compared to the control.
MIC results were well supported with antimicrobial sensitivity data,
as ampicillin/sulbactam and chloramphenicol showed decrease value
of MIC after the biofield treatment. Ampicillin/sulbactam (i.e. 16/8 to
≤8/4 µg/mL) and chloramphenicol (i.e. 16 to ≤8 µg/mL) showed two
folds change in MIC values as compared to the control. Cephalothin
showed an alteration in MIC value i.e. from ≤8 to 16 µg/mL after
biofield treatment. The rest of the tested antimicrobials did not show
any alteration in MIC values with respect to the control.
Efficacy of sulbactam, a β-lactamase inhibitor, in combination with
ampicillin, was well reported and a preferred treatment option against
β-lactam-resistant K. pneumoniae infections. According to Hoffman et
al. the combination of ampicillin/sulbactam was found to have
synergistic effects, which significantly decreased the severity of
pneumonia. Bronchoalveolar lavage cytologic findings, and extent of
macroscopic lesions in lung tissue of the noninoculated regions were
reported as compared to the individual ampicillin or sulbactam [26].
The resistance pattern of ampicillin against K. pneumoniae is because
of two types of chromosomal β-lactamase enzymes being SHV-1 and
LEN-1 [27], and results suggest that biofield treatment might alter
these enzymes and alter the sensitivity pattern. Biofield treatment on
K. pneumoniae has improved the sensitivity profile of ampicillin/
sulbactam and showed decreased MIC value by two-folds, which might
be useful in the future treatment strategy against pneumoniae lung
infection. Multi-drug therapies are another approach against β-
lactamase producing strain of K. pneumoniae, as synergy has been
frequently reported in vitro between β-lactams and aminoglycosides.
According to Jones, a synergistic effect was frequently reported in a
combination of ertapenem and ciprofloxacin [28]. Besides synergistic
effect, antibiotics such as amikacin, gatifloxacin, gentamicin, and
chloramphenicol are the preferred drug of choice with respect to cost,
side effects and many other factors in K. pneumoniae associated
infections [29]. Mr. Trivedi’s biofield energy treatment on K.
pneumoniae showed improved sensitivity pattern of chloramphenicol
and simultaneously decreased the MIC value as compared to the
control. β-lactamases are enzymes that inactivates the β-lactam
containing antibiotic which is present in almost all Gram-negative
bacilli such as E. coli and Klebsiella spp. [30]. Biofield treatment might
alter the production of these enzymes which may result in the
improved sensitivity of antimicrobials.
Organism identification by biochemical reactions
Biochemical study results of control and biofield treated groups are
summarized in Table 3.
S. No. Code Biochemical Control Treated
1 ACE Acetamide - -
2 ADO Adonitol + +
3 ARA Arabinose + +
4 ARG Arginine - -
5 CET Cetrimide - -
6 CF8 Cephalothin - +
7 CIT Citrate + +
8 CL4 Colistin + -
9 ESC Esculin hydrolysis + +
10 FD64 Nitrofurantoin - -
11 GLU Glucose + +
12 H2S Hydrogen sulfide - -
13 IND Indole - -
14 INO Inositol + +
15 K4 Kanamycin - -
16 LYS Lysine + +
17 MAL Malonate + +
18 MEL Melibiose + +
19 NIT Nitrate + -
20 OF/G Oxidation-fermentation/glucose + +
21 ONPG Galactosidase + +
22 ORN Ornithine - -
23 OXI Oxidase - -
24 P4 Penicillin + +
25 RAF Raffinose + +
26 RHA Rhamnose + +
27 SOR Sorbitol + +
28 SUC Sucrose + +
29 TAR Tartrate - -
30 TDA Tryptophan deaminase - -
31 TO4 Tobramycin - -
32 URE Urea + +
33 VP Voges-Proskauer - -
Table 3: Effect of biofield treatment on K. pneumoniae to the vital
processes occurring in living organisms -: negative; +: positive.
The results showed overall 9.09% of tested biochemical altered
reactions as compared to the control. The colistin and nitrate
biochemical showed negative reaction i.e. from (+) positive to (-)
negative as compared to the control. Cephalothin showed positive
reaction i.e. from (-) negative to (+) positive reaction. The rest of tested
biochemicals did not show any alteration in their reaction pattern after
biofield treatment. The biochemical reactions of control K.
pneumoniae were well supported with literature data [31].
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Organism identification by biotype number
Based on the biochemical results, alteration in biotype number was
also observed in the biofield treated K. pneumoniae as compared to the
control. The control group showed biotype number as 7774 4274, while
after treatment altered biotype number was reported as 7774 4272.
However, no change in organism was reported after biofield treatment
with respect to the control. Our research group recently reported the
significant alterations in biochemical reactions followed by the change
in biotype number that was also supported with published data
[19,20]. Biofield treatment might alter some enzymatic reactions in K.
pneumoniae, which resulted in alterations in characteristic
biochemical reactions and biotype number.
Random Amplified Polymorphic DNA (RAPD) analysis
RAPD has been used as a genotyping tool to that is being used to
correlate the genetic similarity or mutations between species of K.
pneumoniae [32]. DNA fingerprinting analysis of the control and
treated K. pneumoniae was identified on the basis of their different and
discriminative RAPD patterns. The simplicity and wide applicability of
RAPD analysis mainly depend on the use of short nucleotide primers,
which were unrelated to known DNA sequences of the target organism
[21]. DNA polymorphism can be efficiently detected using the PCR
primers and identify the inter-strain variations among species in the
treated samples. The degree of relatedness and genetic mapping can be
correlated between similar or different treated sample species [33].
In this experiment, DNA fingerprinting of control and treated
samples using RAPD are shown in Figure 1.
Figure 1: Random amplified polymorphic-DNA fragment patterns
of K. pneumoniae generated using five RAPD primers, RBA 5A,
RBA 10A, RBA 15A, RBA 21A and RBA 22A. 1: Control; 2: Treated
A; 3: Treated A-1; 4: Treated B; 5: Treated B-1; M: 100 bp DNA
Ladder.
The polymorphic bands are marked by arrows in the gel image. The
RAPD patterns of treated samples showed some unique, dissimilar,
common, and polymorphic patterns. DNA polymorphism among the
different treated samples compared with the control were analyzed and
presented in Table 4.
S. No. Primer Nucleotide sequence(5’-3’)
Total no. of
polymorphic bands
Common bands in
control and treated
Unique band
Control TSA TSA-1 TSB TSB-1
1 RBA 5A GTTTCGCTCC 18 11 1 2 1 1 2
2 RBA 10A GTGGATCCGA 15 5 3 1 0 0 0
3 RBA 15A GCGATCCCCA 12 8 1 1 0 0 0
4 RBA 21A CCGCAGCCAA 15 13 0 0 0 0 0
5 RBA 22A AAGAGCCCGT 14 5 1 1 0 2 0
Table 4: DNA polymorphism of K. pneumoniae analyzed by random amplified polymorphic DNA (RAPD) analysis, TSA: treated sample A;
TSA-1: treated sample A-1; TSB: treated sample B; TSB-1: treated sample B-1.
The level of polymorphism between control and treated samples (A,
A1, B, and B1) are summarized in Table 5.
Primer C and TSA C and TSA-1 C and TSB C and TSB-1 TSA and TSA-1 TSB and TSB-1 TSA and TSB TSA-1 and TSB-1
RBA 5A 18% 12% 12% 18% 18% 18% 6% 6%
RBA 10A 30% 15% 15% 23% 10% 0% 15% 8%
RBA 15A 18% 27% 27% 9% 11% 0% 9% 15%
RBA 21A 0% 6% 0% 0% 0% 0% 0% 6%
RBA 22A 13% 6% 20% 6% 10% 20% 5% 0%
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Average polymorphism 15% 13% 14% 11% 9% 7% 7% 7%
Table 5: Level of polymorphism between control and treated K. pneumoniae samples. C: Control; TSA: treated sample A; TSA-1: treated sample
A-1; TSB: treated sample B; TSB-1: treated sample B-1.
The level of polymorphism was found in an average range of 11 to
15% in the treated samples as compared to control after the biofield
treatment. The highest change in DNA sequence was observed in
treated samples with RBA 10A primer as compared to control; whereas
no change was found in treated sample with RBA 21A primer as
compared to control. Thus, results indicates that treatment samples has
genetic variability among organism. RAPD also explains the relevant
degree of genetic diversity, however this technique has the potential to
detected genetic polymorphism throughout the genome [34].
Biofield energy as the complementary medicine is well documented
and considered as alternate medicine approach worldwide. According
to the report of National Health Interview Survey (NHIS), conducted
by the Centers for Disease Control and Prevention's (CDC) and
National Center for Health Statistics (NCHS) till 2007, energy
medicine was practiced almost 4 out of 10 adults in the past 12 months
[35]. Current experiment was designed to demonstrate the impact of
Mr. Trivedi’s biofield treatment on K. pneumoniae for its antimicrobial
susceptibility testing. Further, the molecular methods was performed
to study the genetic alterations and similarities using RAPD
sequencing methods. Increased infection of K. pneumoniae and other
Gram-negative pathogen associated with nosocomial infections have
become a global health problem. Results suggest that biofield
treatment on microorganism can alter the in vitro sensitivity of the
antimicrobials and it might be correlated with acetylation of
antimicrobials that may happen via active drug efflux mechanism.
Increased incidence of nosocomial infections and broad resistance
against broad spectrum antibiotics would be a serious global threat.
Mr. Trivedi’s biofield treatment showed a significant decrease in MIC
values of ampicillin/sulbactam and chloramphenicol along with
improved sensitivity, which suggested an alteration at enzymatic/
genetic level that may modify ligand-receptor interaction. Hence a
cascade of intra-cellular signals may be initiated, accelerated or
inhibited [36], after biofield treatment on pathogenic microbes.
Further, biofield treatment on K. pneumoniae, possible involve
alterations at receptor level due to energy transfer via. biofield
treatment, which may change the receptor drug interactions, which in
turn alter the internal state of the microbe. However, it was reported
that electromagnetic fields might alter the transmembrane
concentration of cell, and will alter the receptor protein molecule.
Biofield treatment might alter the receptor interaction, and results in
altered antibiogram of K. pneumoniae with respect to the control [37].
Conclusion
In summary, it can be concluded that Mr. Trivedi’s biofield energy
treatment on K. pneumoniae has improved the antimicrobial
sensitivity and decreased the MIC value by two folds in case
ampicillin/sulbactam and chloramphenicol. Cephalothin showed
altered antibiogram after biofield treatment as compared to the
control. The biochemical study results showed the alteration of
biochemical reactions of cephalothin, colistin, and nitrate, followed by
change in the biotype number (7774 4272) after biofield treatment as
compared to the control biotype (7774 4274). Using RAPD markers,
the biofield treated samples were characterized and showed
interspecific polymorphic relationship with K. pneumoniae after
biofield treatment. Overall, it seems that Mr. Trivedi’s unique biofield
energy treatment on pathogenic microbes might be used as an
alternate approach to alter the antimicrobial sensitivity.
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